A MVA construct expressing a secretable form of the Dengue virus 3 envelope protein protects immunized mice from dengue-induced encephalitis

• Published in: Vaccine Vol. 34; no. 50; pp. 6120 - 6122
• Main Authors: Quinan, Bárbara R., Versiani, Alice Freitas, da Fonseca, Flávio G.
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier Ltd 07.12.2016; Elsevier Limited
• Subjects: Allergy and Immunology; animal models; Animals; Antibodies, Neutralizing - blood; Antibodies, Viral - blood; dengue; Dengue - prevention & control; Dengue fever; Dengue vaccine; Dengue Vaccines - administration & dosage; Dengue Vaccines - genetics; Dengue Vaccines - immunology; Dengue virus; Dengue Virus - genetics; Dengue Virus - immunology; Developing countries; Disease Models, Animal; Drug Carriers; Encephalitis; Encephalitis model; Encephalitis, Viral - prevention & control; endoplasmic reticulum; Experiments; Female; Flaviviridae; Glycoproteins; Immunization; Immunogenicity; Infections; LDCs; Licenses; Lymphocytes; Mice; Mice, Inbred C57BL; MVA; neutralization; Neutralizing antibodies; Peptides; Proteins; Public health; Recombinant MVA; serotypes; Studies; Vaccines; Vaccinia virus; Vaccinia virus - genetics; Vector-borne diseases; Viral Envelope Proteins - genetics; Viral Envelope Proteins - immunology; Turkey, Ankara; Nabs; rMVA; Encephalitis model; Neutralizing antibodies; DENV; VACV; Recombinant MVA; MVA; Dengue vaccine; modified Vaccinia virus Ankara; neutralizing antibodies; recombinant MVA; vaccinia virus; Dengue virus
• ISSN: 0264-410X; 1873-2518; 1873-2518
• DOI: 10.1016/j.vaccine.2016.10.058

•MVA expressing a DENV protein directed to the ER induces neutralizing antibodies.•Vaccination with MVA expressing a secretable E protein abrogates encephalitis in mice.•MVA expressing a non-secretable E protein does not protect mice from encephalitis. Dengue is no longer restricted to tropical developing countries, but is now a major global public health problem. Despite the recent license approval of the CYD-TDV vaccine in some countries, efforts to develop a more efficient vaccine against Dengue virus (DENV) continue. Herein, we evaluate the immunogenicity and level of protection of two potential vaccines against DENV based on recombinant modified vaccinia virus Ankara (rMVA). The vaccine addressing the Envelope protein from DENV serotype 3 to the endoplasmic reticulum elicited neutralizing antibodies titers which correlate with protection, and also confers protection upon challenge in a mouse model. Our results support the development of a tetravalent dengue vaccine with the further construction of rMVAs expressing proteins from the other DENV serotypes.